Engflag

Scilla Maritima

Quick links to important sections

Scilla Maritima

Scilla Maritima_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Scilla Maritima

Scilla Maritima, commonly known as Squill or Sea Onion, is a historical and contemporary medicinal entity derived from a plant source, primarily known for its action on the cardiovascular and respiratory systems.

Property Description
Active ingredient Scilla glycosides (e.g., Proscillaridin A)
Form Tincture, Syrup, Fluid Extract, Pellets (Homeopathic)
Pharmacological class Cardiac Glycosides, Expectorant
Common use Circulatory support, Mucus clearance
Origin Natural Product (Drimia maritima bulb)

What Type of Medicine is Scilla Maritima (Squill)?

Scilla Maritima is a potent natural product and a type of herbal medicine derived from the dried bulb of the perennial herb Drimia maritima. This plant source places the substance in the Cardiac Glycosides pharmacological class. The primary pharmacological application of this substance is within the cardiovascular field, a role traditionally recognized for centuries.

The Squill bulb yields active compounds, primarily a group of chemicals known as bufadienolides, which established its medicinal role. Because of its core actions, Scilla Maritima is also traditionally classified as a Cardiotonic, meaning it acts upon the heart, and an Expectorant, meaning it influences the respiratory tract.

Composition and Available Forms of Squill

The main active ingredients in the drug entity are a complex of compounds known as Scilla glycosides, most notably Proscillaridin A and Scillaren A. The substance is primarily encountered in liquid oral forms such as a Tincture, Syrup, or Fluid Extract. The Syrup of Squill formulation, which often uses Sucrose as a base, is a distinguishing feature, making it palatable for general use compared to the sharper taste of an alcoholic Tincture.

These pharmaceutical forms utilize the extracted glycosides, which are characterized by their high potency. While often prepared as a single entity drug, it is historically found within certain Compound Syrup formulations intended to combine its actions with other substances.

What is the General Purpose of Scilla Maritima?

The general purpose of Scilla Maritima relates directly to its ability to influence the mechanical action of the heart and stimulate respiratory secretions. Its cardiotonic effect contributes to improved circulatory efficiency, supporting the management of issues related to fluid retention or edema.

Furthermore, its action as an expectorant means the substance has a general purpose in addressing basic respiratory complaints associated with congestion. This is achieved through its indirect influence on the mucous membranes, promoting the production of thinner, more plentiful secretions that aid in the clearance of thick mucus from the airways.

What side effects are possible with Scilla Maritima?

Scilla Maritima (also known as Drimia maritima or Squill) contains cardiac glycosides (cardenolides), which are potent compounds with a well-documented risk profile. This profile is defined by potential cardiotoxicity that can lead to serious and life-threatening adverse reactions.

Safety and Toxicity Profile

Due to the presence of these naturally occurring cardiac glycosides, the substance has a narrow therapeutic index. This means the difference between a potentially beneficial dose and a toxic dose is small, making the risk of poisoning high.

System-Organ Class Key Adverse Reactions (Toxicity)
Cardiovascular System Arrhythmias (irregular heart rhythms), heart block, bradycardia (slow heart rate), and ventricular fibrillation, which can be fatal.
Gastrointestinal System Nausea, vomiting, diarrhea, and abdominal pain are common initial symptoms of toxicity.
Nervous System Symptoms may include generalized weakness, drowsiness, and, in severe cases, seizures.

Clinically Significant Adverse Outcomes

Adverse events associated with the ingestion of its toxic compounds may be classified as life-threatening or severe, potentially resulting in death, requiring inpatient hospitalization, or causing persistent or significant disability. The toxic profile is analogous to that of other cardiac glycoside poisonings.

Safety Classifications and Restrictions

Regulatory authorities in some regions have classified Scilla Maritima as a Banned substance for use in Traditional Medicines and Health Supplements, explicitly due to the presence of cardiac glycosides and the associated toxicity risk. There is particular caution necessary, or prohibition noted, for use in the pregnant population due to the potential for severe adverse outcomes, including congenital anomalies.

Overdose and Emergency Response

Overdose and When to Seek Help

Scilla Maritima (also known as Sea Onion or Squill) contains cardiac glycosides, which are highly potent compounds with a narrow therapeutic index. This means the difference between a therapeutic amount and a toxic, life-threatening amount is very small, making any accidental or excessive exposure a severe medical risk.

Documented Overdose Presentations

Ingestion of the plant, particularly the bulb, has been associated with fatal outcomes due to its toxicity, which closely mimics digitalis poisoning. The primary systems affected are cardiovascular, gastrointestinal, and neurological.

Key manifestations of overdose include:

  • Severe Gastrointestinal Distress: Marked by nausea and persistent vomiting.
  • Neurological Events: Including the onset of seizures.
  • Cardiovascular Collapse: The most dangerous effects, which involve atrioventricular block, ventricular arrhythmias, and hyperkalemia (elevated potassium levels). Death is commonly attributed to refractory ventricular arrhythmias.

Required Emergency Action

Any suspected ingestion or exposure, particularly in cases where the toxic nature of the plant is known, requires immediate medical supervision. Due to the high potential for fatal outcomes from cardiac events, prompt identification of the ingested substance is crucial for guiding effective management. The official response involves supportive treatment, consultation with poison control centers or toxicologists, and may require specialized interventions like cardiac pacing to manage severe heart rhythm disturbances.

Therapeutic Uses of Scilla Maritima

Main Uses and Therapeutic Benefits of Scilla Maritima (Squill)

Scilla Maritima is commonly used for symptomatic assistance across two primary therapeutic domains, addressing symptoms related to systemic imbalance and respiratory congestion. Applications are generally considered in contexts where additional symptomatic support is needed for discomfort associated with conditions characterized by symptoms of mild cardiac stress, chronic bronchitis, and fluid accumulation.

The substance is relevant for easing symptoms in therapeutic areas involving both cardiovascular support and airway clearance.

Managing Fluid Retention and Mild Circulatory Symptoms

The medicine is used to help with symptoms linked to organ-specific functional stress, such as those related to a mildly stressed heart. This support may be applied in settings marked by temporary physiological imbalance that leads to fluid accumulation or edema. It provides support that helps ease the overall symptom burden associated with these conditions involving episodic or fluctuating manifestations.

Easing Symptoms of Congestive Coughs and Mucus

Squill is also applied in addressing symptom clusters that may become intense or disruptive in the respiratory tract. It contributes to improved comfort during symptomatic periods by easing the burden of congestion and may assist with managing symptoms that interfere with daily functioning.

Quick Fact: Focus on Symptomatic Support: Edema The substance may assist with managing symptoms of fluid retention that interfere with daily functioning, particularly when linked to symptoms of circulatory stress.

Regulatory References

  1. Egyptian Drug Authority Herbal Monograph on Drimia Maritima

Eligibility and Restrictions for Use

Who can and cannot use Scilla Maritima?

The population eligibility for Scilla Maritima (Squill) is severely restricted by regulatory authorities due to the presence of potent cardiac glycosides and their narrow therapeutic index. Use is generally intended only for the Adult Population and requires medical supervision.

Eligibility Status Population/Condition
Absolutely Contraindicated Patients with Second- or Third-Degree Atrioventricular (AV) Block.
Patients with Hypercalcemia or Hypokalemia (electrolyte imbalance).
Patients with Hypertrophic Cardiomyopathy or Ventricular Tachycardia.
Must be Avoided Pregnant women (due to reported abortifacient action).
Lactating (Breastfeeding) women.
Not Recommended Children under 12 years old.
Patients with Impaired Renal Function or Impaired Hepatic Function.
Patients with pre-existing Stomach or Bowel Problems.

Official regulatory documents define these specific cardiac, metabolic, and organ-function conditions as absolute non-eligibility criteria. Use in older adults (geriatric patients) requires caution due to increased sensitivity and potential for reduced organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Scilla Maritima, due to its classification as a Cardiac Glycoside, has officially documented interaction patterns that increase the risk of toxicity when co-administered with specific medicinal products.

Interaction Classifications and Restrictions

Co-administration with other Digitalis Glycosides (such as Digoxin) is formally restricted and is considered a contraindicated combination by regulatory authorities due to the high risk of pharmacological overlap and additive toxicity. Furthermore, Scilla glycosides are contraindicated when a patient has Potassium Deficiency (Hypokalemia), a condition that significantly potentiates the cardiac effects and toxicity of this drug class.

Documented Interactions

Interactions are generally classified as causing an increase in effectiveness and side effects (toxicity) through two main pharmacodynamic mechanisms:

  • Electrolyte-Mediated Potentiation: The co-administration of Diuretic Drugs (saluretics), Corticosteroids (Glucocorticoids), and Stimulant Laxatives can promote Potassium depletion, which functionally increases the drug’s toxicity.
  • Direct Synergism: The concurrent use of Antiarrhythmic Agents like Quinidine may increase toxicity through documented pharmacodynamic synergism.

Population-Specific Notes

Regulatory documents state that use is not recommended for patients with impaired hepatic function or impaired renal function. This constraint is due to the potential for reduced clearance and drug accumulation, which magnifies the severity of any existing drug interaction.

Mechanism of Action

Na^+/ K^+- ATPase Inhibition and Cardiac Cascade

Scilla Maritima contains cardiac glycosides, primarily scillaren A, which inhibit the Na^+/ K^+- ATPase (sodium-potassium pump) on the cell membrane. This primary interaction is the biological target. The subsequent inhibition leads to an increase in intracellular sodium concentration. This elevation in sodium concentration reduces the driving force for the Na^+/ Ca^2+ exchanger ( NCX), consequently resulting in an increased intracellular calcium concentration. The resulting rise in calcium facilitates increased calcium binding to troponin C, promoting actomyosin cross-bridge formation in myocardial tissue.

Modulation of Renal Transport Proteins

In addition to its cardiac effects, Scilla Maritima modulates the activity of transport proteins within the renal tubules. This pathway modulation primarily affects the reabsorption of ions and water in the kidney, contributing to altered volume regulation.

Dosage and Administration Information

The administration of Scilla Maritima is typically associated with the specific dosage form. For preparations such as homeopathic pellets, the method of intake is the oral route with a requirement for sublingual dissolution. There are documented ranges for standardized powders and liquid extracts.

The dose for pellets is 10 per single administration for adults and adolescents (12 years and older). For children aged 2 to 11 years, the dose is 5 pellets. This administration follows a multiple-times-per-day frequency pattern, typically 3 to 4 times daily.

Common practice indicates that administration should commence at the onset of symptoms. The course duration is short-term; use is intended to stop if symptoms persist for more than 3 days or if they worsen. A specific age-group administration rule applies to the youngest users: for children under 2 years, the 5-pellet dose involves a preparation step of dissolution in a small amount of water before being administered. These guidelines reflect use based on traditional homeopathic practice.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Scilla Maritima (Squill)

Evidence for Circulatory Support and Fluid Regulation

Research into Scilla maritima's study for circulatory support and fluid regulation centers on the Scilla glycosides, which belong to a class of compounds examined for patterns related to heart muscle contraction. Research examined measurements related to heart muscle contraction, a physiological action studied for its role in the cardiovascular system.

Studies conducted during earlier periods, often designed as Randomized Controlled Trials (RCTs), was studied for its potential role in patients with conditions characterized by fluctuating or episodic manifestations related to the circulatory system. Researchers monitored outcomes related to fluid balance, such as changes in urine output, in patients experiencing outcomes related to systemic or functional imbalance, such as edema (fluid retention).

Evidence quality for this indication is assessed as low certainty. Many of the trials are older, meaning they may not meet the same methodological standards as contemporary studies. Furthermore, the findings were mixed and often relied on specific, sometimes non-standardized extracts or isolated glycosides. As a result, the data are still emerging regarding the consistent measured patterns of currently available Squill products for addressing heart-related symptoms.

Evidence for Symptomatic Relief of Congestive Coughs

The research exploring Scilla maritima for respiratory support focuses on its traditional classification as an expectorant, which was studied for aiding the clearance of thick mucus from the airways. This research examined settings with varying symptom burdens, often studying the substance in traditional preparations such as Squill-Oxymel.

Pilot Randomized Controlled Trials (RCTs) have explored short-term changes in individuals experiencing outcomes describing episodic or acute changes, such as chronic, productive coughs. Studies monitored patient-reported outcomes describing perceived discomfort related to cough frequency and intensity, as well as the subjective ease of mucus clearance. Findings describe patterns observed in the studies where participants was observed in some studies to experience changes in their respiratory symptom scores.

Evidence quality for the expectorant role is assessed as moderate-low certainty. Research highlights changes measured during the study period but often involved sample sizes were modest and the results apply only to the populations studied using that specific traditional formulation. The relevance of these findings to other preparations is not fully established.

Research on Extended-Duration Use and Follow-up

For most traditional medicines, the research base often emphasizes short-term symptom management. Research examined outcomes over defined time intervals, typically lasting only a few weeks to two months.

Long-term effects are not fully established for Scilla maritima. There is limited information for long-term outcomes that could confirm the stability of observed symptom patterns. Existing studies provide context but not individual predictions regarding sustained use. The research landscape currently lacks robust, peer-reviewed data from trials with follow-up durations were limited that would allow a deeper understanding of maintenance effects over extended periods.

Evidence in Specific Patient Groups and Populations

Clinical studies on Scilla maritima historically involved adults experiencing mild to moderate symptoms. However, the available data is limited regarding many specific patient subgroups.

Data for certain groups remain insufficient. For instance, there is limited information or short-term measured patterns specifically on older adults that accounts for age-related physiological changes. Research does not determine whether an individual will respond similarly across various population groups, and therefore, subgroup findings are uncertain due to limited evidence.

Evidence Gaps and Areas of Uncertainty

Research on Scilla maritima contributes to understanding symptom patterns but also presents clear gaps. The evidence quality varies across studies, largely due to a reliance on older research methodologies and small study sizes. Comparative evidence is lacking in modern, high-quality RCTs that rigorously compare current Scilla preparations against established treatments. This means that while research describes patterns, evidence quality remains low for broad conclusions.

Key Studies & References

  1. Egyptian Drug Authority Herbal Monograph on Drimia Maritima (Scilla)
  2. WHO Anatomical Therapeutic Chemical (ATC) Classification: C01AB Scilla glycosides

Frequently Asked Questions (FAQ)

Common questions about Scilla Maritima (FAQ)

Q: Is Scilla Maritima available over-the-counter or does it require a prescription?

The drug is currently classified as an Over-the-Counter (OTC) drug in its regulated homeopathic forms. This status is documented on official drug labels, such as those listed by the NIH DailyMed system.

Q: What kind of regulatory body oversees the manufacture of Scilla Maritima products?

In the United States, the Food and Drug Administration (FDA) oversees the marketing and labeling of the product. Manufacturers are required to list their establishment and operational details on official drug labels, such as those found on NIH DailyMed.

Q: Is Scilla Maritima approved for use in children or adolescents?

The official labeling for some preparations includes dosage instructions for both adolescents (ge 12 years) and younger children (2-11 years). However, other regulatory documents also state that the substance is not recommended for children under 12 years old. Official documents suggest consultation with a healthcare professional regarding use in this population.

Q: Do any official documents describe Scilla Maritima as a 'strong' medicine?

While the term 'strong' is non-specific, regulatory documents describe the active components as potent cardiac glycosides. Furthermore, official safety information highlights that the substance has a narrow therapeutic index, meaning the difference between an intended dose and a toxic dose is small, reflecting its inherent potency.

Q: What are the most common side effects people report when using Scilla Maritima?

Regulatory safety documents indicate that gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain are commonly described as initial symptoms of toxicity. This reflects the drug's narrow therapeutic index, where the line between an intended effect and potential poisoning is small.

Q: Is it normal to feel a mild stomach upset when first taking Scilla Maritima?

Official documents describe that gastrointestinal upset, including nausea and vomiting, is described as a common initial sign of toxicity. Due to the presence of potent cardiac glycosides, this substance has a narrow safety margin. These symptoms are described in the context of the drug’s known toxicity profile.

Q: Does Scilla Maritima have a warning about driving or operating machinery?

Official regulatory monographs state that studies on the effect of Scilla Maritima on the ability to drive and use machines have not been performed. Therefore, specific warnings regarding impairment from official sources are not available.

Q: What is the risk of having a serious allergic reaction to Scilla Maritima?

Official product warnings clearly state that allergy to any ingredient is a criterion for non-use. This is a standard safety precaution, and the presence of any known allergy to the active or inactive components is a basis for non-use.

Q: Does Scilla Maritima have a specific warning about sun exposure or skin sensitivity?

Yes, official monographs related to the substance advise caution regarding exposure to sunlight after use. This information indicates that a potential for photosensitivity is noted in some regulatory documents.

Q: Do official sources mention Scilla Maritima causing any changes to sleep patterns?

Official regulatory documents describe drowsiness as a potential nervous system symptom related to the drug's toxicity profile. While this does not directly address general sleep patterns (like insomnia), the description relates to the drug's known toxicity profile.

Q: What do patient information leaflets typically say about the potential for feeling dizzy after taking Scilla Maritima?

Official safety documents describe that potential nervous system symptoms related to toxicity include generalized weakness and drowsiness. While dizziness is not explicitly listed, these symptoms are described in the context of the drug’s known toxicity profile.

Q: Is the research on Scilla Maritima primarily focused on human or animal studies?

The research reviewed in official documents on the substance includes Randomized Controlled Trials (RCTs) and Pilot RCTs. This indicates a documented focus on studies involving human subjects to assess symptom patterns and outcomes.

How should Scilla Maritima be stored and disposed of?

How to Store and Dispose of Scilla Maritima?

The storage and disposal requirements for Scilla Maritima are strictly defined by the regulatory classification of its toxic active compounds, such as Scilliroside.

Detail Official Regulatory Statement
Child-protection storage Must be Store locked up (P405) and Keep out of reach of children (P102).
Light/moisture protection Protect from sunlight (P410) and Protect from moisture (P232).
Packaging-related rules Keep container tightly closed (P233) and in its original container (P234).
Disposal instructions Dispose of contents/container according to local, regional, national, and international regulations (P501).

Official documents mandate that the product must be stored under conditions that maintain its chemical stability and prevent accidental access. This requires securing the medicine to prevent accidental poisoning, which is a mandatory safety precaution. Disposal must adhere to strict environmental and controlled-waste protocols, requiring that the product Avoid release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Scilla Maritima found in:

A-Z Index: